NCT06276738View on ClinicalTrials.gov

The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

March 1, 2034

Study Completion Date

May 1, 2034

Conditions

Pancreatic CancerJaundiceAbdominal Neoplasm

Interventions

DIAGNOSTIC_TEST

LINFU® (Low Intensity Non-Focused Ultrasound excitation of the pancreas)

Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes. A contrast agent will be administered IV at five minute intervals. The patient will then receive a dose of secretin and the the patient's pancreatic juice will then be collected for a total of 15 minutes.

All Listed Sponsors

lead

Adenocyte, LLC

INDUSTRY

NCT06276738 - The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease | Biotech Hunter | Biotech Hunter